Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.40 USD
+0.01 (0.72%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.43 +0.03 (2.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Brokerage Reports
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 201 - 220 ( 273 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Plans to Out-License XIPERE - Cash Runway Extended into Q3:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Presentations on SCS-Microinjection Applications at ASRS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE /ME-NIU October 19 PDUFA: We Anticipate Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Presentations on SCS-Microinjection Applications at OIS - ASRS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
License Agreement with Aura Extends SCS Platform into Ocular Oncology
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q1: Cash Runway into Q1:20 Covers Likely XIPERE(TM) Approval in October
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Presentations Support SCS-Microinjection Applications In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE ME-NIU NDA Accepted by FDA; PDUFA Date Set to October 19, 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
ME-NIU NDA Submitted; We Anticipate FDA Acceptance of Filing in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L